2024-05-15T12:46:32-05:00 2023-06-30 BDO USA 200 PARK AVENUE 38TH FLOOR NEW YORK NY 10166 990 2022-07-01 133020943 SAMUEL WAXMAN CANCER RESEARCH FOUNDATION % SAMUEL WAXMAN SAMU 2128674502 420 LEXINGTON AVENUE Suite 825 NEW YORK NY 10170 WILLIAM SULLIVAN EXECUTIVE DIRECTOR 2128674502 2024-05-14 true WILLIAM SULLIVAN 999009999 Paul Hammerschmidt P01384178 2128858000 2024-05-14 3 2022 2023-04-26 12:10:37Z WILLIAM T SULLIVAN 420 LEXINGTON AVENUE suite 825 NEW YORK NY 10170 6625374 false X WWW.WAXMANCANCER.ORG X 1980 NY The Samuel Waxman Cancer research Foundation (The "Foundation") funds innovative research to bring faster cures to patients. (CONTINUED ON SCHEDULE O) 28 26 5 133 0 0 4702594 3898721 0 0 3501 10259 0 99794 4706095 4008774 1031225 1842599 0 0 1123678 1369557 0 99794 714956 742843 692675 2897746 4004625 1808349 4149 6125031 6175563 301266 310385 5823765 5865178 X THE SAMUEL WAXMAN CANCER RESEARCH FOUNDATION (THE "FOUNDATION") FUNDS INNOVATIVE RESEARCH TO BRING FASTER CURES TO PATIENTS. (CONTINUED ON SCHEDULE O) false false 2928996 1842599 0 The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The foundation is a pioneer in cancer research focusing on uncovering the causes of cancer and reprogramming cancer cells. We dedicate ourselves to delivering tailored, minimally toxic treatments to patients. Our mission is to eradicate cancer by bridging the gap between lab science and the patient. Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since our inception in 1976, the foundation has awarded more than $100 million to support the work of more than 200 researchers across the globe. 2928996 true true false false false false false false false false true false false false true true true false false false true true false true true false false true true true false false false false false false false false true false false false false false false false false true 34 0 true 5 true false false false false false true true false false false false false false X 28 26 true false false false false false false true true false false true true true true true true true true false NY X X X SAMUEL WAXMAN 2128674502 420 LEXINGTON AVENUE SUITE 825 NEW YORK NY 10170 William T Sullivan Executive Director 50.0 0.0 X 337000 0 54880 Samuel Waxman MD Director-CEO 20.0 0.0 X X 220000 0 0 Suzanna C Houston Director of Special Projects 40.0 0.0 X 154523 0 33553 Wylie Tene Director of Marketing & Comm. 40.0 0.0 X 135625 0 30721 Michael Nierenberg Chairman 2.0 0.0 X X 0 0 0 Spencer Waxman President 2.0 0.0 X X 0 0 0 Dena K Weiner Vice-President 2.0 0.0 X X 0 0 0 Thomas Conway Treasurer 2.0 0.0 X X 0 0 0 Nicholas Santoro Assistant Treasurer 2.0 0.0 X X 0 0 0 Gerard J Joyce Secretary 2.0 0.0 X X 0 0 0 Christine Arlotta Director 1.0 0.0 X 0 0 0 Fredrick W Barney Director 1.0 0.0 X 0 0 0 Ethan Dmitrovsky MD Director 1.0 0.0 X 0 0 0 Kenneth Fishel Director 1.0 0.0 X 0 0 0 James Frankel Director 1.0 0.0 X 0 0 0 Dennis A Herman Director 1.0 0.0 X 0 0 0 Linda Herman Director 1.0 0.0 X 0 0 0 W David Hinkelman Director 1.0 0.0 X 0 0 0 James A Ingram Director 1.0 0.0 X 0 0 0 Gary Jacob Director 1.0 0.0 X 0 0 0 Matthew Lyons Director 1.0 0.0 X 0 0 0 Peeyush Misra Director 1.0 0.0 X 0 0 0 Gary Nolan Director 1.0 0.0 X 0 0 0 Riva Ariella Ritvo-Slifka Director 1.0 0.0 X 0 0 0 Lewis A Rubin Director 1.0 0.0 X 0 0 0 Howard Shlafmitz Director 1.0 0.0 X 0 0 0 Baron Silverstein Director 1.0 0.0 X 0 0 0 Joseph Steffa Director 1.0 0.0 X 0 0 0 Marc Taub Director 1.0 0.0 X 0 0 0 Scott Waxman Director 1.0 0.0 X 0 0 0 Ari Zagdanski Director 1.0 0.0 X 0 0 0 GREGORY FABIJANCZUK CFO (EFF. 1/2023) 40.0 0.0 X 0 0 0 847148 0 119154 4 false true false Mt Joy LLC 235 Park Ave South NEW YORK NY 10003 ENTERTAINMENT SVCS 140000 1 2039642 1859079 52775 3898721 0 10679 0 10679 0 0 0 0 0 1249996 1250416 -420 -420 -420 1465978 2039642 1366184 99794 99794 0 0 0 0 0 0 0 4008774 0 110053 1617599 1617599 225000 225000 0 0 0 833704 483893 128878 220933 0 295415 161228 49437 84750 21151 9095 4442 7614 135304 58181 28414 48709 83983 36113 17636 30234 0 0 159607 68631 33518 57458 0 99794 99794 0 59369 25529 12467 21373 0 165241 71053 34700 59488 0 0 177877 76487 37354 64036 21500 9245 4515 7740 0 71620 71620 0 0 5900 2537 1239 2124 16953 7290 3560 6103 TAXES & LICENSES 1830 1830 MISCELLANEOUS EXPENSES 12778 5495 2683 4600 4004625 2928996 360673 714956 0 231346 2752445 59085 2767349 2828744 71488 60938 0 0 0 0 0 0 0 0 512469 340714 59379 33140 8762 26239 12518 2539620 0 10613 0 0 0 0 0 78264 6125031 6175563 118187 88979 4785 0 161067 161823 0 0 0 0 0 0 0 0 0 0 17227 59583 301266 310385 X 3218468 3005881 2605297 2859297 5823765 5865178 6125031 6175563 X 4149 38748 -1484 X false true X true false X 4055312 5113708 2494884 4702594 3898721 20265219 0 0 4055312 5113708 2494884 4702594 3898721 20265219 585421 19679798 23559 93742 15925 3501 10679 147406 0 0 20412625 0.96410 0.99280 X 0.00000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 39479 16468 23011 19900 16672 3228 26239 0 OPERATING LEASE LIABILITY 59583 59583 X 3947728 38748 38748 3908980 99794 99794 4008774 3906315 1484 1484 3904831 99794 99794 4004625 SCHEDULE D, PART X, LINE 2: UNDER GAAP, AN ORGANIZATION MUST RECOGNIZE THE TAX BENEFIT ASSOCIATED WITH TAX POSITIONS TAKEN FOR TAX RETURN PURPOSES WHEN IT IS MORE LIKELY THAN NOT THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION BY A TAXING AUTHORITY. THE FOUNDATION DOES NOT BELIEVE IT HAS TAXEN ANY MATERIAL UNCERTAIN TAX POSITIONS AND, ACCORDINGLY, IT HAS NOT RECORDED ANY LIABILITY FOR UNRECOGNIZED TAX BENEFITS. THE FOUNDATION HAS FILED FOR AND RECEIVED INCOME TAX EXEMPTIONS IN THE JURISDICTIONS WHERE IT IS REQUIRED TO DO SO. ADDITIONALLY, THE FOUNDATION HAS FILED INTERNAL REVENUE SERVICE FORM 990 INFORMATION RETURNS, AS REQUIRED, AND ALL OTHER APPLICABLE RETURNS IN JURISDICTIONS WHERE SO REQUIRED. FOR THE YEAR ENDED JUNE 30, 2023, THERE WERE NO INTEREST OR PENALTIES RECORDED OR INCLUDED IN THE STATEMENT OF ACTIVITIES. THE FOUNDATION IS SUBJECT TO ROUTINE AUDIT BY A TAXING AUTORITY. AS OF JUNE 30, 2023, THE FOUNDATION WAS NOT SUBJECT TO ANY EXAMINATION BY A TAXING AUTHORITY. SCHEDULE D, PART XI, LINE 4B: FUNDRAISING EXPENSE ............. $99,794 SCHEDULE D, PART XII, LINE 4B: BAD DEBT FOR UNCOLLECTIBLE PLEDGES ............ $ (1,484) SCHEDULE D, PART XII, LINE 4B FUNDRAISING EXPENSE ............ $99,794 true East Asia and the Pacific Grantmaking 112500 North America Grantmaking 75000 Middle East and North Africa Grantmaking 37500 225000 225000 East Asia and the Pacific RESEARCH GRANT 75000 CHECK East Asia and the Pacific RESEARCH GRANT 37500 Check Middle East and North Africa RESEARCH GRANT 37500 Check North America RESEARCH GRANT 37500 Check North America RESEARCH GRANT 37500 Check 5 false false false false false false SCHEDULE F, PART I, LINE 2: GRANTEES ARE REQUIRED TO SUBMIT PROGRESS REPORTS TO THE SAMUEL WAXMAN CANCER RESEARCH FOUNDATION. X X true ERICA LINDEN FINEBERG 333 E 68TH STREET NEW YORK NY 10065 FUNDRAISING false 0 37919 -37919 KOSZYN COMPANY 41 EAST 11TH STREET NEW YORK NY 10003 FUNDRAISING false 0 61875 -61875 0 99794 -99794 NY Gala 2688516 1528935 1159581 48712 209535 140000 661540 Hamptons 303472 110211 193261 58100 135161 10 513632 400496 113136 52388 60748 3505620 2039642 1465978 101100 267635 140000 857449 1366184 99794 true Albert Einstein College of Medicine 1300 Morris Park Avenue New York NY 10461 830621846 501(C)(3) 37500 N/A N/A RESEARCH GRANT The Univ of North Carolina at Chapel Hill 104 Airport Drive Chapel Hill NC 27599 566001393 501(C)(3) 37500 N/A N/A Research Grants The General Hospital Corp 55 Fruit Street Boston MA 02114 042697983 501(C)(3) 37500 N/A N/A Research Grants Johns Hopkins University 1650 Orleans street Baltimore MD 21263 520595110 501(C)(3) 137500 N/A N/A Research Grants St Judes Hospital 262 Danny Thomas Place Memphis TN 38105 620646012 501(C)(3) 37500 N/A N/A Research Grants University of California 1855 Folsom Street San Francisco CA 94143 946036493 501(C)(3) 25000 N/A N/A Research Grants Leidos Biomedical Research Inc 1050 Boyles Street Frederick MD 21702 330653185 501(C)(3) 37500 N/A N/A Research Grants University of Florida Board of Trustees 33Tigert Hall Gainesville FL 32611 596002052 501(C)(3) 37500 N/A N/A Research Grants Ichan School of Medicine at Mount Sianai One Gustae L Levy Place New York NY 10229 366171197 501(C)(3) 29099 N/A N/A Research Grants University of Maryland 1420 N Charles St Baltimore MD 21202 526002033 501(C)(3) 37500 N/A N/A Research Grants Weil Cornell School of Medicine 525 East 68th Street New York NY 10065 131623978 501(C)(3) 37500 N/A N/A Research Grants Regents University of California 490 Illinois Street San Francisco CA 94143 946036493 501(C)(3) 75000 N/A N/A Research Grants Whitehead Insitute for Biomedical Research 455 Main Street Cambridge MA 021242102 061043412 501(C)(3) 37500 N/A N/A Research Grants The Salk Insitute for Bilogical Studies 10010 N Torrey Pines Rd La Jolla CA 92037 952160097 501(C)(3) 75000 N/A N/A Research Grants University of Miami 1320 S Dixie Hwy Coral Gables FL 33146 590624458 501(C)(3) 37500 N/A N/A Research Grants Memorial Sloan Kettering 1275 York Avenue New York NY 10021 131924236 501(C)(3) 237500 N/A N/A Research Grants Rutgers Cancer Institute of New Jersey 195 Lil Albany St New Brunswick NJ 08901 202959012 501(C)(3) 12500 N/A N/A Research Grants University of Notre Dame 1234 N Notre Dame Ave South Bend IN 46617 350868188 501(C)(3) 37500 N/A N/A Research Grants Trustees University of Pennsylvania 341 Walnut Street Philadelphia PA 19104 231352685 501(C)(3) 125000 N/A N/A Research Grants Stanford University 485 Broadway Redwood City CA 94063 941156365 501(C)(3) 200000 N/A N/A Research Grants Dana-Faber Cancer Institute 450 Brookline Avenue Boston MA 02241 042263040 501(C)(3) 100000 N/A N/A Research Grants Bringham and Women's Hospital Research 75 Francis St Boston MA 02115 042312909 501(C)(3) 25000 N/A N/A Research Grants The Buck Institute for Research on Aging 8001 Redwood Blvd Novato CA 94945 943030609 501(C)(3) 25000 N/A N/A Research Grants Baylor College of Medicine 1 Baylor Plaza Houston TX 77030 741613878 501(C)(3) 25000 N/A N/A Research Grants 24 SCHEDULE I, PART I, LINE 2: ALL GRANT RECIPIENTS HAVE TO SUBMIT A FINANCIAL REPORT INDICATING HOW THE GRANT WAS SPENT, IF ALL THE FUNDS WERE NOT SPENT THIS CAN AFFECT FUTURE GRANT FUNDING TO THE RECIPIENT. X X X false false false false false false false true false William T Sullivan Executive Director 327000 0 10000 0 0 0 13954 0 40926 0 391880 0 0 0 Samuel Waxman MD Director-CEO 220000 0 0 0 0 0 0 0 0 0 220000 0 0 0 Suzanna C Houston Director of Special Projects 139523 0 15000 0 0 0 15832 0 17721 0 188076 0 0 0 Wylie Tene Director of Marketing & Comm. 125625 0 10000 0 0 0 13000 0 17721 0 166346 0 0 0 PART I, LINE 7: SCHEDULE J, PART II, COLUMN (B)(II) REPORTS PERFORMANCE BASED BONUSES THAT WERE DETERMINED BY THE COMPENSATION COMMITTEE AND WAS APPROVED BY THE BOARD. X 5 52775 MARKET QUOTATION false true false PART I, COLUMN (B): THE NUMERICAL DATA IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS RECEIVED. FORM 990, PART I, LINE 1, (CONTINUATION): IN ADDITION TO SUPPORTING ONGOING COLLABORATIVE RESEARCH IN SPECIFIC CANCERS, OUR SCIENTISTS ARE INVESTIGATING THE BIOLOGY OF CANCER TO FIND TREATMENTS ACROSS DISEASE TYPES. THE WORLD CLASS SCIENTISTS WHO REPRESENTS OUR INSTITUTE WITHOUT WALLS SHARE INFORMATION AND RESOURCES TO SPEED THE PACE OF CANCER RESEARCH. FOUNDATION INVESTIGATORS HAVE MADE MAJOR BREAKTHROUGHS IN CANCER, FROM DISCOVERING PATHWAYS TO DELIVER DRUGS TO IDENTIFYING POTENTIAL MINIMALLY TOXIC AND NOVEL THERAPIES. FORM 990, PART III, LINE 1(CONTINUATION): IN ADDITION TO SUPPORTING ONGOING COLLABORATIVE RESEARCH IN SPECIFIC CANCERS, OUR SCIENTISTS ARE INVESTIGATING THE BIOLOGY OF CANCER TO FIND TREATMENTS ACROSS THE DISEASE. FORM 990, PART VI, SECTION A, LINE 2: BOARD MEMBERS, Spencer WAXMAN and Scott Waxman are the sons of Samuel Waxman. BOARD MEMBERS, DENNIS A HERMAN AND LINDA HERMAN HAVE FAMILY A RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B: FORM 990 WAS PREPARED BY A NATIONALLY RECOGNIZED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. THE TREASURER AND OTHER EXECUTIVE BOARD MEMBERS ARE ACTIVELY INVOLVED WITH THE REVIEW OF THE AUDITED FINANCIAL STATEMENTS. THE FORM 990 IS REVIEWED AND COMPARED WITH THE AUDITED FINANCIAL STATEMENTS AND A COPY IS PROVIDED TO ALL BOARD MEMBERS BEFORE BEING FILED WITH IRS. FORM 990, PART VI, SECTION B, LINE 12C: THE FOUNDATION ANNUALLY, DURING JUNE'S BOARD MEETING, PRIOR TO THE START OF THE FISCAL YEAR, JULY 1ST, EVERY BOARD MEMBER HAS TO FILL OUT AND RETURN A CONFLICT OF INTEREST FORM. FORM 990, PART VI, SECTION B, LINE 15A AND 15B: THE COMPENSATION COMMITTEE, WHICH COMPRISES OF BOARD MEMBERS DETERMINE THE COMPENSATION FOR THE CEO, EXECUTIVE DIRECTOR, KEY EMPLOYEES AND OFFICERS BASED UPON PERFORMANCE REVIEW SUCH AS THE CREDENTIALS, SKILLS, EXPERIENCE AND EXPERTISE REQUIRED FOR THESE POSITIONS. SURVEYS AND RESEARCH ARE DONE, INCLUDING THE COMPARISON OF OTHER ORGANIZATION'S FORM 990 TO DETERMINE THE REASONABLE COMPENSATION. THE DECSION IS COMTEMPORANEOUSLY DOCUMENTED IN THE BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 19: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE FOUNDATION'S AUDITED FINANCIAL STATEMENTS AND FORM 990 ARE AVAILABLE ON THE FOUNDATION'S WEBSITE (WWW.WAXMANCANCER.ORG). FORM 990, PART XI, LINE 9: BAD DEBT FOR UNCOLLECTIBLE PLEDGES ............. $ (1,484)